StemCell Therapy

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Privacy Policy (Updated: October 8, 2015):

hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide

Continue reading here:
Developments in Regenerative Medicine: FDA Announces Plans to ... - JD Supra (press release)

Valeria Canto-Soler at work in the lab at the Gates Center for Regenerative Medicine.

When Valeria Canto-Soler, Ph.D., was a biology student in Argentina, she dreamed of a career studying elephants and other African wildlife in their natural habitat.

But life took her on a different journey. In July, Canto-Soler joined the Department of Ophthalmology and the Gates Center for Regenerative Medicine as the Doni Solich Family Endowed Chair in Ocular Stem Cell Research.

I like to joke about it, she says. Instead of spending my life studying animals in the wilds of Africa, Im in a dark room sitting in front of a microscope.

After an international search, Canto-Soler also was named director of CellSight, the Ocular Stem Cell and Regeneration Research Program, in partnership with the Gates Center and the Department of Ophthalmology. She also will be an Associate Professor of Ophthalmology at the CU Anschutz School of Medicine.

This $10 million ocular stem cell and regeneration program initiative began with a $5 million grant from the Gates Frontiers Fund to research the potential for stem cells to treat age-related macular degeneration, the leading cause of blindness in people ages 50 and older.

I dreamed of launching a stem cell research program like this for years, she says. The leadership at both the Gates Center and the Department of Ophthalmology has the same vision that I have. Working together, we can make it happen.

Canto-Soler grew up in Mendoza, Argentina, a city on the eastern side of the Andes Mountains. Similar to Denver in that its nestled in the foothills, Mendozas close proximity to the mountains gave her the opportunity to hike, explore and marvel at the natural wildlife she encountered.

But when it came to a career choice, it was more difficult for her to decide how to direct her love of nature and biology. In contrast to the U.S., students in Argentina have to decide on a career early.

Its a very important decision and there are very few chances for you to change your mind after that, she says.

As a young biology student, Canto-Soler found herself drawn to the study of the human nervous system and how the sense organs work.

Year by year, I felt more and more fascinated by the biology of the human body, she says. In the last two years of biology school, I started to work in a lab studying the nervous system. That defined my future.

Canto-Soler earned a B.S. in Biology from the University of Cordoba School of Natural Sciences, Cordoba, Argentina in 1996. In 2002, she completed a Ph.D. in Biomedical Sciences at the Austral University School of Medicine in Buenos Aires.

After she earned her Ph.D., Canto-Soler had the opportunity to explore new vistas. She was accepted as a Fellow with the Retinal Degenerations Research Center in the Department of Ophthalmology at Johns Hopkins University School of Medicine in Baltimore. She worked with renowned scientist Ruben Adler, MD, at the Wilmer Eye Institute.

I was so excited the focus of his research was the development of the eye, Canto-Soler says. It was perfect for me.

She thought her fellowship would provide her the knowledge and experience she could take back to Argentina, but she found new challenges to keep her in the U.S. When her mentor, Dr. Adler, died in 2007, she took over his role at Wilmer to continue their work.

In 2014, Canto-Soler and her team created a miniature human retina in a petri dish, using human stem cells. The mini retinas had functioning photoreceptor cells capable of sensing light. This cutting-edge research opened up the potential to take cells from a patient who suffers from a particular retinal disease, such as macular degeneration, and use them to generate mini retinas that would recapitulate the disease of the patient; this allows studying the disease on a human context directly, rather than depending on animal models.

This research could lead to personalized medicine and drug treatments for specific patient needs. At CellSight, Canto-Soler will work with clinicians and members of the Gates Center to create patient registries and cell banking. She hopes her research will someday result in cell-based treatments; retinal patches, for example, which could be transplanted into a patients eye, possibly curing blindness.

Once you transplant a retinal patch, the cells have to establish all the right connections with the patients own retinal cells in order to process the information and produce a visual image, she says. No one really knows how to do that yet.

But shes confident the clinicians from the Department of Ophthalmology, and the researchers at CellSight and the Gates Center, will work together to make the dream a reality.

Im definitely a dreamer, Canto-Soler says. I never imagined we could generate human mini retinas in a petri dish. And to see that happen made me a believer. I believe our scientific dreams can come true if we pursue them in the right way.

The letters and emails she receives from those who have family members or friends suffering from sight problems or blindness inspire her. Theyre also looking for answers.

Its what gets me motivated to come to work every day, she says. Im excited to think about how we could help people and the impact that would make in their lives.

Continue reading here:
Canto-Soler joins team at Gates Center for Regenerative Medicine to develop cell-based treatments - CU Anschutz Today (press release)

What if one day, we could teach our bodies to self-heal like a lizards tail, and make severe injury or disease no more threatening than a paper cut?

Or heal tissues by coaxing cells to multiply, repair or replace damaged regions in loved ones whose lives have been ravaged by stroke, Alzheimers or Parkinsons disease?

Such is the vision, promise and excitement in the burgeoning field of regenerative medicine, now a major ASU initiative to boost 21st-century medical research discoveries.

ASU Biodesign Institute researcher Nick Stephanopoulos is one of several rising stars in regenerative medicine. In 2015, Stephanopoulos, along with Alex Green and Jeremy Mills, were recruited to the Biodesign Institutes Center for Molecular Design and Biomimetics (CMDB), directed by Hao Yan, a world-recognized leader in nanotechnology.

One of the things that that attracted me most to the ASU and the Biodesign CMDB was Haos vision to build a group of researchers that use biological molecules and design principles to make new materials that can mimic, and one day surpass, the most complex functions of biology, Stephanopoulos said.

I have always been fascinated by using biological building blocks like proteins, peptides and DNA to construct self-assembled structures, devices and materials, and the interdisciplinary and highly collaborative team in the CMDB is the ideal place to put this vision into practice.

Yans research center uses DNA and other basic building blocks to build their nanotechnology structures only at a scale 1,000 times smaller than the width of a human hair.

Theyve already used nanotechnology to build containers to specially deliver drugs to tissues, build robots to navigate a maze or nanowires for electronics.

To build a manufacturing industry at that tiny scale, their bricks and mortar use a colorful assortment of molecular Legos. Just combine the ingredients, and these building blocks can self-assemble in a seemingly infinite number of ways only limited by the laws of chemistry and physics and the creative imaginations of these budding nano-architects.

Learning from nature

The goal of the Center for Molecular Design and Biomimetics is to usenatures design rulesas an inspiration in advancing biomedical, energy and electronics innovation throughself-assembling moleculesto create intelligent materials for better component control and for synthesis intohigher-order systems, said Yan, who also holds the Milton Glick Chair in Chemistry and Biochemistry.

Prior to joining ASU, Stephanopoulos trained with experts in biological nanomaterials, obtaining his doctorate with the University of California Berkeleys Matthew Francis, and completed postdoctoral studies with Samuel Stupp at Northwestern University. At Northwestern, he was part of a team that developed a new category of quilt-like, self-assembling peptide and peptide-DNA biomaterials for regenerative medicine, with an emphasis in neural tissue engineering.

Weve learned from nature many of the rules behind materials that can self-assemble. Some of the most elegant complex and adaptable examples of self-assembly are found in biological systems, Stephanopoulos said.

Because they are built from the ground-up using molecules found in nature, these materials are also biocompatible and biodegradable, opening up brand-new vistas for regenerative medicine.

Stephanopoulos tool kit includes using proteins, peptides, lipids and nucleic acids like DNA that have a rich biological lexicon of self-assembly.

DNA possesses great potential for the construction of self-assembled biomaterials due to its highly programmable nature; any two strands of DNA can be coaxed to assemble to make nanoscale constructs and devices with exquisite precision and complexity, Stephanopoulos said.

Proof all in the design

During his time at Northwestern, Stephanopoulos worked on a number of projects and developed proof-of-concept technologies for spinal cord injury, bone regeneration and nanomaterials to guide stem cell differentiation.

Now, more recently, in a new studyin Nature Communications, Stephanopoulos and his colleague Ronit Freeman in the Stupp laboratory successfully demonstrated the ability to dynamically control the environment around stem cells, to guide their behavior in new and powerful ways.

In the new technology, materials are first chemically decorated with different strands of DNA, each with a unique code for a different signal to cells.

To activate signals within the cells, soluble molecules containing complementary DNA strands are coupled to short protein fragments, called peptides, and added to the material to create DNA double helices displaying the signal.

By adding a few drops of the DNA-peptide mixture, the material effectively gives a green light to stem cells to reproduce and generate more cells. In order to dynamically tune the signal presentation, the surface is exposed to a soluble single-stranded DNA molecule designed to grab the signal-containing strand of the duplex and form a new DNA double helix, displacing the old signal from the surface.

This new duplex can then be washed away, turning the signal off. To turn the signal back on, all that is needed is to now introduce a new copy of single-stranded DNA bearing a signal that will reattach to the materials surface.

One of the findings of this work is the possibility of using the synthetic material to signal neural stem cells to proliferate, then at a specific time selected by the scientist, trigger their differentiation into neurons for a while, before returning the stem cells to a proliferative state on demand.

One potential use of the new technology to manipulate cells could help cure a patient with neurodegenerative conditions like Parkinsons disease.

The patients own skin cells could be converted to stem cells using existing techniques. The new technology could help expand the newly converted stem cells back in the lab and then direct their growth into specific dopamine-producing neurons before transplantation back to the patient.

People would love to have cell therapies that utilize stem cells derived from their own bodies to regenerate tissue, Stupp said. In principle, this will eventually be possible, but one needs procedures that are effective at expanding and differentiating cells in order to do so. Our technology does that.

In the future, it might be possible to perform this process entirely within the body. The stem cells would be implanted in the clinic, encapsulated in the type of material described in the new work, and injected into a particular spot. Then the soluble peptide-DNA molecules would be given to the patient to bind to the material and manipulate the proliferation and differentiation of transplanted cells.

Scaling the barriers

One of the future challenges in this area will be to develop materials that can respond better to external stimuli and reconfigure their physical or chemical properties accordingly.

Biological systems are complex, and treating injury or disease will in many cases necessitate a material that can mimic the complex spatiotemporal dynamics of the tissues they are used to treat, Stephanopoulos said.

It is likely that hybrid systems that combine multiple chemical elements will be necessary; some components may provide structure, others biological signaling and yet others a switchable element to imbue dynamic ability to the material.

A second challenge, and opportunity, for regenerative medicine lies in creating nanostructures that can organize material across multiple length scales. Biological systems themselves are hierarchically organized: from molecules to cells to tissues, and up to entire organisms.

Consider that for all of us, life starts simple, with just a single cell. By the time we reach adulthood, every adult human body is its own universe of cells, with recent estimates of 37 trillion or so. The human brain alone has 100 billion cells or about the same number of cells as stars in the Milky Way galaxy.

But over the course of a life, or by disease, whole constellations of cells are lost due to the ravages of time or the genetic blueprints going awry.

Collaborative DNA

To overcome these obstacles, much more research funding and recruitment of additional talent to ASU will be needed to build the necessary regenerative medicine workforce.

Last year, Stephanopoulos research received a boost with funding from the U.S. Air Forces Young Investigator Research Program (YIP).

The Air Force Office of Scientific ResearchYIP award will facilitate Nicks research agenda in this direction, and is a significant recognition of his creativity and track record at the early stage of his careers, Yan said.

Theyll need this and more to meet the ultimate challenge in the development of self-assembled biomaterials and translation to clinical applications.

Buoyed by the funding, during the next research steps, Stephanopoulos wants to further expand horizons with collaborations from other ASU colleagues to take his research teams efforts one step closer to the clinic.

ASU and the Biodesign Institute also offer world-class researchers in engineering, physics and biology for collaborations, not to mention close ties with the Mayo Clinic or a number of Phoenix-area institutes so we can translate our materials to medically relevant applications, Stephanopoulos said.

There is growing recognition that regenerative medicine in the Valley could be a win-win for the area, in delivering new cures to patients and building, person by person, a brand-new medicinal manufacturing industry.

Stephanopoulos recent research was carried out at Stupps Northwesterns Simpson Querrey Institute for BioNanotechnology. The National Institute of Dental and Craniofacial Research of the National Institutes of Health (grant 5R01DE015920) provided funding for biological experiments, and the U.S. Department of Energy, Office of Science, Basic Energy Sciences provided funding for the development of the new materials (grants DE-FG01-00ER45810 and DE-SC0000989 supporting an Energy Frontiers Research Center on Bio-Inspired Energy Science (CBES)).

The paper is titled Instructing cells with programmable peptide DNA hybrids. Samuel I. Stupp is the senior author of the paper, and post-doctoral fellows Ronit Freeman and Nicholas Stephanopoulos are primary authors.

See the rest here:
Bio-inspired Materials Give Boost to Regenerative Medicine - Bioscience Technology

The global regenerative medicine market size is expected to reach USD 5.59 billion by 2025, according to this new report. Increased prevalence of neurodegenerative, orthopedic, and other aging-related disorders in geriatric population coupled with rising global geriatric population is anticipated to drive market growth.

Developments in biotechnology have enabled gaining in-depth knowledge pertaining to cell division and differentiation as well as the metabolism mechanism of various cells. This enriched knowledge, coupled with emergence of novel streams of biotechnology such as gene therapy and nanotechnology, further prospered use of cell-based technology in therapeutic treatment.

Identification of ability of stem cells to develop into various different cell lines further propelled the advancements in regenerative medicine. Frequent media exposure due to regulatory as well as ethical controversies around embryonic stem cells has increased awareness among the masses. This encouraged researchers to explore and develop other potential fields for similar applications, such as induced pluripotent stem cells (iPSC).

Furthermore, the emergence of gene therapy techniques with potential to rectify and restore effects of gene mutations in cells is under development. Conditions caused due to Single Nucleotide Polymorphism (SNP) as well as mutations that induce degenerative characteristics are primarily targeted.

Companies Mentioned

Key Topics Covered:

1 Research Methodology

2. Executive Summary

3. Regenerative Medicnie Market Variables, Trends & Scope

4. Regenerative Medicine Market: Product Type Estimates & Trend Analysis

5. Regenerative Medicine Market: Therapeutic Category Estimates & Trend Analysis

6. Regenerative Medicine Market: Regional Estimates & Trend Analysis, by Product And Therapeutic Category

7. Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/research/948x9s/regenerative

Media Contact:

Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/regenerative-medicine-market-to-reach-55-billion-by-2025-increased-prevalence-of-neurodegenerative-orthopedic--other-aging-related-disorders-300506534.html

SOURCE Research and Markets

http://www.researchandmarkets.com

Read the original here:
Regenerative Medicine Market to Reach $5.5 Billion by 2025 ... - PR Newswire (press release)

SAN CARLOS, Calif.--(BUSINESS WIRE)--Cellerant Therapeutics, Inc., a clinical-stage company developing innovative immunotherapies for hematologic malignancies and other blood-related disorders, today announced it has been awarded a grant from the California Institute for Regenerative Medicine (CIRM) for up to $6.86 million to support preclinical development and the filing of an Investigational New Drug application (IND) for CLT030-ADC, Cellerants antibody-drug conjugate (ADC) product for the treatment for acute myeloid leukemia (AML). AML is an aggressive cancer with high relapse rates and low overall survival, which are thought to be due to the persistence of leukemic stem cells that are relatively resistant to current chemotherapy regimens. CLT030-ADC targets C-type-like lectin 1 (CLL1), a cell surface antigen highly expressed on leukemic stem cells but not on normal hematopoietic stem and progenitor cells.

CIRM is an agency of the State of California whose mission is to accelerate stem cell treatments to patients with unmet medical needs. CIRM grants are awarded through a competitive process which includes rigorous review and evaluation by independent scientific and medical experts.

"We are honored to receive this award from CIRM, which will help us advance the development of CLT030-ADC, said Ram Mandalam, Ph.D., President and Chief Executive Officer of Cellerant. Based on target characteristics and preclinical results, CLT030-ADC has the potential to increase survival and become a first-in-class treatment for AML patients. We are excited to be working with CIRM to develop this novel therapeutic for an unmet medical need.

Our mission here at CIRM is to support novel stem cell-based therapeutics, including those that target cancer stem cells, added Maria Millan, M.D., interim President and CEO of CIRM. Cancer stem cells are believed to play a key role in tumor formation and growth, so attacking them has the potential to improve patient outcomes in deadly diseases such as AML.

CLT030-ADC consists of an antibody targeting CLL1 linked to a DNA-damaging cytotoxic payload. CLL1 is an antigen expressed specifically on AML cancer stem cells and not on normal hematopoietic stem cells. The Company and others have shown that CLL1 is expressed in approximately 90% of all AML patient types, including all French American British classifications, all cytogenetic risk categories, and in patients independent of FLT-3 status. In preclinical AML models, CLT030-ADC demonstrated complete target-dependent tumor regression. Importantly, CLT030-ADC should have minimal effect on the formation of

normal blood cell types because CLL1 is not expressed on normal hematopoietic stem cells and minimally on progenitor cells. This would potentially be an important safety advantage compared to other targeted therapies for AML where the target antigen is expressed on normal stem and progenitor cells, such as CD33.

About Cellerant Therapeutics

Cellerant Therapeutics is a clinical-stage company developing innovative cell- and antibody-based immunotherapies for hematologic malignancies and other blood-related disorders. Cellerants CLT-008 (human myeloid progenitor cells) is a universal cell therapy for the treatment of neutropenia. Chemotherapy-induced neutropenia is a severe side effect of many chemotherapy regimens, particularly for AML and other hematologic malignancies. CLT-008 is currently in a randomized, controlled Phase 2 clinical trial in patients with AML. Cellerants is developing two antibody drug-conjugate (ADC) product candidates: CLT030-ADC, intended to treat AML by selectively targeting and killing leukemic stem and blast cells, and CLT012-ADC, which could be a potential treatment for AML and a number of solid tumors. For more information, visit: http://www.cellerant.com

The rest is here:
Cellerant Therapeutics, Inc. Awarded $6.86 Million Grant From California Institute for Regenerative Medicine to ... - Business Wire (press release)

In a new studyin Nature Communications, Stephanopoulos and his colleague Ronit Freeman successfully demonstrated the ability to dynamically control the environment around stem cells, to guide their behavior in new and powerful ways. Credit: Northwestern University

What if one day, we could teach our bodies to self-heal like a lizard's tail, and make severe injury or disease no more threatening than a paper cut?

Or heal tissues by coaxing cells to multiply, repair or replace damaged regions in loved ones whose lives have been ravaged by stroke, Alzheimer's or Parkinson's disease?

Such is the vision, promise and excitement in the burgeoning field of regenerative medicine, now a major ASU initiative to boost 21st-century medical research discoveries.

ASU Biodesign Institute researcher Nick Stephanopoulos is one of several rising stars in regenerative medicine. In 2015, Stephanopoulos, along with Alex Green and Jeremy Mills, were recruited to the Biodesign Institute's Center for Molecular Design and Biomimetics (CMDB), directed by Hao Yan, a world-recognized leader in nanotechnology.

"One of the things that that attracted me most to the ASU and the Biodesign CMDB was Hao's vision to build a group of researchers that use biological molecules and design principles to make new materials that can mimic, and one day surpass, the most complex functions of biology," Stephanopoulos said.

"I have always been fascinated by using biological building blocks like proteins, peptides and DNA to construct self-assembled structures, devices and materials, and the interdisciplinary and highly collaborative team in the CMDB is the ideal place to put this vision into practice."

Yan's research center uses DNA and other basic building blocks to build their nanotechnology structuresonly at a scale 1,000 times smaller than the width of a human hair.

They've already used nanotechnology to build containers to specially deliver drugs to tissues, build robots to navigate a maze or nanowires for electronics.

To build a manufacturing industry at that tiny scale, their bricks and mortar use a colorful assortment of molecular Legos. Just combine the ingredients, and these building blocks can self-assemble in a seemingly infinite number of ways only limited by the laws of chemistry and physicsand the creative imaginations of these budding nano-architects.

Learning from nature

"The goal of the Center for Molecular Design and Biomimetics is to use nature's design rules as an inspiration in advancing biomedical, energy and electronics innovation through self-assembling molecules to create intelligent materials for better component control and for synthesis into higher-order systems," said Yan, who also holds the Milton Glick Chair in Chemistry and Biochemistry.

Prior to joining ASU, Stephanopoulos trained with experts in biological nanomaterials, obtaining his doctorate with the University of California Berkeley's Matthew Francis, and completed postdoctoral studies with Samuel Stupp at Northwestern University. At Northwestern, he was part of a team that developed a new category of quilt-like, self-assembling peptide and peptide-DNA biomaterials for regenerative medicine, with an emphasis in neural tissue engineering.

"We've learned from nature many of the rules behind materials that can self-assemble. Some of the most elegant complex and adaptable examples of self-assembly are found in biological systems," Stephanopoulos said.

Because they are built from the ground-up using molecules found in nature, these materials are also biocompatible and biodegradable, opening up brand-new vistas for regenerative medicine.

Stephanopoulos' tool kit includes using proteins, peptides, lipids and nucleic acids like DNA that have a rich biological lexicon of self-assembly.

"DNA possesses great potential for the construction of self-assembled biomaterials due to its highly programmable nature; any two strands of DNA can be coaxed to assemble to make nanoscale constructs and devices with exquisite precision and complexity," Stephanopoulos said.

Proof all in the design

During his time at Northwestern, Stephanopoulos worked on a number of projects and developed proof-of-concept technologies for spinal cord injury, bone regeneration and nanomaterials to guide stem cell differentiation.

Now, more recently, in a new study in Nature Communications, Stephanopoulos and his colleague Ronit Freeman in the Stupp laboratory successfully demonstrated the ability to dynamically control the environment around stem cells, to guide their behavior in new and powerful ways.

In the new technology, materials are first chemically decorated with different strands of DNA, each with a unique code for a different signal to cells.

To activate signals within the cells, soluble molecules containing complementary DNA strands are coupled to short protein fragments, called peptides, and added to the material to create DNA double helices displaying the signal.

By adding a few drops of the DNA-peptide mixture, the material effectively gives a green light to stem cells to reproduce and generate more cells. In order to dynamically tune the signal presentation, the surface is exposed to a soluble single-stranded DNA molecule designed to "grab" the signal-containing strand of the duplex and form a new DNA double helix, displacing the old signal from the surface.

This new duplex can then be washed away, turning the signal "off." To turn the signal back on, all that is needed is to now introduce a new copy of single-stranded DNA bearing a signal that will reattach to the material's surface.

One of the findings of this work is the possibility of using the synthetic material to signal neural stem cells to proliferate, then at a specific time selected by the scientist, trigger their differentiation into neurons for a while, before returning the stem cells to a proliferative state on demand.

One potential use of the new technology to manipulate cells could help cure a patient with neurodegenerative conditions like Parkinson's disease.

The patient's own skin cells could be converted to stem cells using existing techniques. The new technology could help expand the newly converted stem cells back in the laband then direct their growth into specific dopamine-producing neurons before transplantation back to the patient.

"People would love to have cell therapies that utilize stem cells derived from their own bodies to regenerate tissue," Stupp said. "In principle, this will eventually be possible, but one needs procedures that are effective at expanding and differentiating cells in order to do so. Our technology does that."

In the future, it might be possible to perform this process entirely within the body. The stem cells would be implanted in the clinic, encapsulated in the type of material described in the new work, and injected into a particular spot. Then the soluble peptide-DNA molecules would be given to the patient to bind to the material and manipulate the proliferation and differentiation of transplanted cells.

Scaling the barriers

One of the future challenges in this area will be to develop materials that can respond better to external stimuli and reconfigure their physical or chemical properties accordingly.

"Biological systems are complex, and treating injury or disease will in many cases necessitate a material that can mimic the complex spatiotemporal dynamics of the tissues they are used to treat," Stephanopoulos said.

It is likely that hybrid systems that combine multiple chemical elements will be necessary; some components may provide structure, others biological signaling and yet others a switchable element to imbue dynamic ability to the material.

A second challenge, and opportunity, for regenerative medicine lies in creating nanostructures that can organize material across multiple length scales. Biological systems themselves are hierarchically organized: from molecules to cells to tissues, and up to entire organisms.

Consider that for all of us, life starts simple, with just a single cell. By the time we reach adulthood, every adult human body is its own universe of cells, with recent estimates of 37 trillion or so. The human brain alone has 100 billion cells or about the same number of cells as stars in the Milky Way galaxy.

But over the course of a life, or by disease, whole constellations of cells are lost due to the ravages of time or the genetic blueprints going awry.

Collaborative DNA

To overcome these obstacles, much more research funding and recruitment of additional talent to ASU will be needed to build the necessary regenerative medicine workforce.

Last year, Stephanopoulos' research received a boost with funding from the U.S. Air Force's Young Investigator Research Program (YIP).

"The Air Force Office of Scientific Research YIP award will facilitate Nick's research agenda in this direction, and is a significant recognition of his creativity and track record at the early stage of his careers," Yan said.

They'll need this and more to meet the ultimate challenge in the development of self-assembled biomaterials and translation to clinical applications.

Buoyed by the funding, during the next research steps, Stephanopoulos wants to further expand horizons with collaborations from other ASU colleagues to take his research team's efforts one step closer to the clinic.

"ASU and the Biodesign Institute also offer world-class researchers in engineering, physics and biology for collaborations, not to mention close ties with the Mayo Clinic or a number of Phoenix-area institutes so we can translate our materials to medically relevant applications," Stephanopoulos said.

There is growing recognition that regenerative medicine in the Valley could be a win-win for the area, in delivering new cures to patients and building, person by person, a brand-new medicinal manufacturing industry.

Explore further: New technology to manipulate cells could help treat Parkinson's, arthritis, other diseases

More information: Ronit Freeman et al. Instructing cells with programmable peptide DNA hybrids, Nature Communications (2017). DOI: 10.1038/ncomms15982

Original post:
Bio-inspired materials give boost to regenerative medicine - Medical Xpress

ISSCA 5TH INTERNATIONAL SYMPOSIUM TO TAKE PLACE AT THE HOTEL SOFITEL IN RABAC THIS SEPTEMBER 30

Global Stem Cells Group, a global network of practitioners, doctors, researchers, and medical advocates that work in tandem to advance the study of regenerative medicine and stem cell development in our world today, this week, through their Stem Cell Conference subsidiary branch, officially announced their International Society for Stem Cells Application (ISSCA) 5th International Regenerative Medicine Symposium will officially take place at the Hotel Sofitel in Rabac.

Occurring this September 30, 2017, the symposium stands to bring together the industrys leading thinkers and doctors for days of collaboration.

To complement the hosting of the symposium, Global Stem Cells Group also announced a scientific program with three different modules that will be made available to event attendees.

We are constantly developing new events, programs, and educational opportunities that provide doctors and students with the ability to learn about regenerative medicine in a live and supportive environment, said Dr. Benito Novas, Founder and Owner of Global Stem Cells Group. We are incredibly excited to be hosting our symposium at the Hotel Sofitel, and we look forward to administering our scientific program to all who are interested.

Module 1, Biologic and Molecular basis for Regenerative Medicine, includes cellular culture and expansion, therapeutic potential, bioactive agents, plus much more. Module 2, Therapeutic Applications: Adult Stem Cells from Bench to Bedside, goes through regenerative orthopedics, protocols, and clinical experiences for students. Lastly, Module 3, Regulations, Marketing and Global Overview of the Stem Cell Industry, is a U.S. Research Policy and Stem Cells overview of the FDA regulatory process today.

To learn more about the program, visit http://www.stemcellgroup.org.

To learn more about the event, visit: http://www.stemcellconference.org.

About Global Stem Cells Group

Read more from the original source:
International Regenerative Medicine Symposium will officially take place in Rabat, Morocco - PRUnderground (press release)

WASHINGTON, DC--(Marketwired - Aug 18, 2017) - The Alliance for Regenerative Medicine (ARM) released today its most recent quarterly data report, offering an in-depth look at cell therapy, gene therapy, tissue engineering and broader global regenerative medicine sector trends and metrics in the second quarter and first half of 2017.

Using information provided by ARM's data partner Informa, the quarterly data report details industry-specific statistics compiled from more than 822 cell therapy, gene therapy, tissue engineering and other regenerative medicine companies worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events and current legislative and regulatory priorities.

The Q2 2017 data report also features expert perspectives from ARM member representatives and other key stakeholders, highlighting important focus areas for the sector:

Expert perspective on the growing interest and advantages of induced pluripotent stem cells as a therapeutic platform, with insights from:

Addressing the unique aspects of market access and reimbursement policy for cell and gene therapies, with insights from:

"At mid-point 2017, this sector has nearly or actually surpassed 2016 year-end totals by several metrics, signifying a renewed uptick in dealmaking and partnering activity across the sector," said Janet Lynch Lambert, ARM's Chief Executive Officer. "We are looking forward to an eventful second half of the year, with several anticipated high-profile product approvals and additional clinical progress in several key therapeutic areas."

Highlighted findings from the Q2 2017 data report include:

ARM will continue to update this information through new reports to be released after the close of each quarter, tracking sector performance, key financial information, clinical trial numbers and clinical data events.

The report is available online here. For more information, please visit http://www.alliancerm.org or contact Lyndsey Scull at lscull@alliancerm.org.

About The Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 270 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org

Go here to read the rest:
The Alliance for Regenerative Medicine Releases Q2 2017 Data ... - Benzinga

NEW YORK, Aug. 16, 2017 /PRNewswire/ -- "Global collagen & gelatin market for regenerative medicine projected to grow at a CAGR of 10.1% and 7.8% respectively."

The global collagen market for regenerative medicine is projected to grow from USD 420.6 million in 2017 to USD 679.9 million by 2022, at a CAGR of 10.1% during the forecast period.

Read the full report: http://www.reportlinker.com/p05064743/Collagen-Gelatin-Market-for-Regenerative-Medicine-by-Source-Bovine-Porcine-Marine-Application-Wound-Care-Orthopedic-Cardiovascular-Value-and-Volume-Analysis-Global-Forecast-to.html

The global gelatin market for regenerative medicine is projected to grow from USD 65.2 million in 2017 to USD 94.9 million by 2022, at a CAGR of 7.8% during the forecast period. The key factors propelling the growth of the global collagen and gelatin market for regenerative medicine include rising prevalence of chronic diseases, rapid growth in aging population, and growing government & private funding to support the development of regenerative medicine. However, the availability of alternative biomaterials for regenerative medicine is expected to restrain the growth of this market.

"The marine collagen segment is expected to grow at the highest CAGR in the global collagen market for regenerative medicine." On the basis of source, the global collagen market for regenerative medicine has been classified into bovine collagen, porcine collagen, marine collagen, and other sources. In 2017, the bovine collagen segment is expected to command the largest share of the global collagen market for regenerative medicine. However, owing to advantages, such as low immunogenicity and high biocompatibility the marine collagen segment is projected to grow at the highest CAGR during the forecast period.

"The orthopedic segment is expected to grow at the highest CAGR in the global collagen market for regenerative medicine." On the basis of application, the global collagen market for regenerative medicine has been segmented into orthopedic, wound care, cardiovascular, and other applications. In 2017, the orthopedic applications segment is expected to command the largest share of the global collagen market for regenerative medicine. However, owing to factors such as rising prevalence of chronic wounds, the wound care segment is projected to register the highest CAGR during the forecast period.

"Asia-Pacific to witness the highest growth during the forecast period." North America held the largest share of the collagen market for regenerative medicine and gelatin market for regenerative medicine, while Asia-Pacific is expected to witness the highest growth during 2017 to 2022 in both the markets.

The high growth in the collagen market for regenerative medicine can primarily be attributed to the large number of CVD patients and diabetics with DFU (diabetic foot ulcers) in the region, increasing number of research studies, and increasing focus of industry players on emerging APAC countries. Similarly, the large number of patients suffering from skin burns & brain tumors and increasing number of research studies in the region are the major factors driving the growth of the APAC market.

Break of primary participants was as mentioned below: By Company Type Tier 145%, Tier 240% and Tier 315% By Designation C-level41%, Director Level30%, Others29% By Region North America38%, Europe31%, Asia-Pacific19%, RoW12%

The major players operating in the global collagen market for regenerative medicine include Integra LifeSciences Holding Corporation (U.S.), Collagen Matrix, Inc. (U.S.), Collagen Solutions plc (U.K.), Royal DSM (Netherlands), Vornia Biomaterials, Ltd. (Ireland), SYMATESE (France), and NuCollagen, LLC. (U.S.). Similarly, the major players operating in the global gelatin market for regenerative medicine include GELITA AG (Germany), Nitta Gelatin, Inc. (Japan), and PB Gelatin (Belgium).

Research Coverage: The report analyzes the global collagen and gelatin market for regenerative medicine and aims at estimating market size and future growth potential of this market based on various segments such as source, application, and region. The report also includes an in-depth regulatory analysis for various regions across the globe and competitive analysis of the key players in this market along with their company profiles, product offerings, and recent developments.

Reasons to Buy the Report The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned four strategies.

This report provides insights on the following pointers: Market Penetration: Comprehensive information on product portfolios offered by the top players in the global collagen and gelatin market for regenerative medicine. The report analyzes the global collagen and gelatin market for regenerative medicine by source, application, and region Market Development: Comprehensive information about lucrative emerging markets the report analyzes the markets for collagens and gelatins for regenerative medicine across various regions Market Diversification: Exhaustive information about new services or service enhancements, growing geographies, recent developments, and investments in the global collagen and gelatin market for regenerative medicine Competitive Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the global collagen and gelatin market for regenerative medicine

Read the full report: http://www.reportlinker.com/p05064743/Collagen-Gelatin-Market-for-Regenerative-Medicine-by-Source-Bovine-Porcine-Marine-Application-Wound-Care-Orthopedic-Cardiovascular-Value-and-Volume-Analysis-Global-Forecast-to.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/collagen--gelatin-market-for-regenerative-medicine-by-source-bovine-porcine-marine-application-wound-care-orthopedic-cardiovascular-value-and-volume-analysis---global-forecast-to-2022-300505537.html

Continued here:
Collagen & Gelatin Market for Regenerative Medicine (by Source ... - PR Newswire (press release)

SAN FRANCISCO, CA--(Marketwired - August 18, 2017) - In an update on this company's clinical cell therapy programs targeting blood cancers and osteoarthritis in the knee, Gabrielle Zhou of Maxim Group describes progress that sets the stage for "value inflection."

Included in this article is: Cellular Biomedicine Group Inc.'s(NASDAQ: CBMG)

Zhou summed up Cellular Biomedicine Group Inc.'s recent activities in an Aug. 9 research report. "CBMG's cell therapy programs continue to make progress," she wrote. "We expect to see data from both the CARD-1 and CALL-1 chimeric antigen receptor T-cell (CAR-T) studies by 2017E, setting the stage for a value inflection as CBMG becomes a Phase 2 CAR-T player."

The analyst also noted the company has enough cash to get to that stage. "CBMG ended the period with $27M in cash," Zhou noted. "At the current burn rate, we estimate CBMG has sufficient capital to fund through topline data releases (by 2017E) from its CARD-1 and CALL-1 studies, which should represent catalysts for the stock."

Continue reading this article:'Keep a Close Eye On' This Regenerative Medicine Firm

About Streetwise Reports -- The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

DISCLOSURES:

The following company mentioned in this article is a billboard sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. Cellular Biomedicine Group Inc. paid Streetwise Reports to distribute this press release on its behalf. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.

Please see the end of the article for the complete disclosures: 'Keep a Close Eye On' This Regenerative Medicine Firm

See more here:
Streetwise Reports Examines One Regenerative Medicine Firm to ... - Markets Insider

The global collagen market for regenerative medicine is projected to grow from USD 420.6 Million in 2017 to USD 679.9 Million by 2022, at a CAGR of 10.1% during the forecast period.

The global gelatin market for regenerative medicine is projected to grow from USD 65.2 Million in 2017 to USD 94.9 Million by 2022, at a CAGR of 7.8% during the forecast period. The key factors propelling the growth of the global collagen and gelatin market for regenerative medicine include rising prevalence of chronic diseases, rapid growth in aging population, and growing government & private funding to support the development of regenerative medicine.

The report analyzes the global collagen & gelatin market for regenerative medicine by source, application, and region. On the basis of source, the global collagen market for regenerative medicine has been segmented into bovine collagen, porcine collagen, marine collagen, and other sources. In 2017, the bovine collagen segment is expected to command the largest share of the global collagen market for regenerative medicine. The large share of this segment is attributed to the lower cost and extensive availability of bovine collagen.

Similarly, on the basis of source, the global gelatin market for regenerative medicine has been segmented into bovine gelatin, porcine gelatin, and gelatin from other sources. In 2017, the bovine gelatin segment is expected to command the largest share of the global gelatin market for regenerative medicine. Owing to its extensive availability, this segment is also projected to register the highest CAGR during the forecast period.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Collagen Market for Regenerative Medicine, By Source

7 Gelatin Market for Regenerative Medicine, By Source

8 Collagen Market for Regenerative Medicine, By Application

9 Gelatin Market for Regenerative Medicine, By Application

10 Collagen Market for Regenerative Medicine, By Region

11 Gelatin Market for Regenerative Medicine, By Region

12 Competitive Landscape

13 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/jrw4ql/collagen_and

Media Contact:

Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/7748-million-collagen--gelatin-market-for-regenerative-medicine-2017---global-forecast-to-2022-300505917.html

SOURCE Research and Markets

http://www.researchandmarkets.com

The rest is here:
$774.8 Million Collagen & Gelatin Market for Regenerative Medicine ... - PR Newswire (press release)

NEW YORK, Aug. 16, 2017 /PRNewswire/ -- Factors driving the growth of this market include the increasing number of genomics research activities for studying diseases; advances in biobanking and the growing trend of conserving cord blood stem cells of newborns; government & private funding to support regenerative medicine research, and the growing need for cost-effective drug discovery and development. On the other hand, the growth of this market is hindered to some extent due to the high cost of automation and issues related to biospecimen sample procurement.

Read the full report: http://www.reportlinker.com/p05064741/Biobanking-Market-by-Product-and-Service-Equipment-Consumables-Services-Software-Sample-Type-Blood-Products-Human-Tissues-Cell-Lines-Nucleic-Acids-Application-Regenerative-Medicine-Life-Science-Clinical-Research-Global-Forecast-to.html

"Automated storage is expected to register the highest CAGR during the forecast period" The biobanking market is classified by storage type into manual and automated storage. The automated storage type segment is expected to grow at a higher rate during the forecast period. This is attributed to launch of new and advanced automated storage equipment and increasing demand for the quality storage of samples.

"Regenerative medicine to dominate the market during the forecast period"The biobanking market is segmented based on applications regenerative medicine, life science research, and clinical research. In 2017, the regenerative medicine segment is expected to command the largest share and is also estimated to grow at the fastest rate as compared to other segments. This can be attributed to increasing research activities in the field of regenerative medicine and rising demand for well-annotated and quality biosamples for research.

"Asia-Pacific is estimated to grow at the highest CAGR during the forecast period" Geographically, the biobanking market is dominated by North America, followed by Europe. The Asia-Pacific region is estimated to grow at the fastest rate which can be attributed to the large population in China and India, increasing research in regenerative medicine, and improving life sciences research infrastructure in the region.

The primary interviews conducted for this report can be categorized as follows:

The key players in the biobanking market include Thermo Fisher Scientific Inc. (U.S.), Tecan Group Ltd. (Switzerland), Qiagen N.V. (Germany), Hamilton Company (U.S.), Brooks Automation (U.S.), TTP Labtech Ltd (U.K.), VWR Corporation (U.S.), Promega Corporation (U.S.), Worthington Industries [(Taylor Wharton, U.S.)], Chart Industries (U.S.), Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Micronic (Netherlands), LVL Technologies GmbH & Co. KG (Germany), Panasonic Healthcare Holdings Co. Ltd (Japan), Greiner Bio One [Greiner Holding AG, Austria)], Biokryo GmbH (Germany), Biobank AS (Norway), Biorep Technologies Inc. (U.S.), Cell & Co Bioservices (France), RUCDR infinite biologics (U.S.), Modul-Bio (France), CSols Ltd (U.K.), Ziath (U.K.), and LabVantage Solutions Inc. (U.S.).

Study Coverage:The report analyses the biobanking market by product and service, sample type, storage type, application and regions. Apart from comprehensive geographic & product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market.

Market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the type, products, applications, end users, and regions.

Key benefits of buying the Report:This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:

Read the full report: http://www.reportlinker.com/p05064741/Biobanking-Market-by-Product-and-Service-Equipment-Consumables-Services-Software-Sample-Type-Blood-Products-Human-Tissues-Cell-Lines-Nucleic-Acids-Application-Regenerative-Medicine-Life-Science-Clinical-Research-Global-Forecast-to.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

Contact Clare: rel="nofollow">clare@reportlinker.comUS:(339) 368 6001 Intl:+1 339 368 6001

View original content:http://www.prnewswire.com/news-releases/biobanking-market-by-product-and-serviceequipment-consumables-services-software-sample-type-blood-products-human-tissues-cell-lines-nucleic-acids-application-regenerative-medicine-life-science-clinical-research---g-300505662.html

SOURCE Reportlinker

See the rest here:
Biobanking Market by Product and Service(Equipment, Consumables, Services, Software), Sample Type (Blood ... - Markets Insider

BANGKOK, Aug. 17, 2017 /PRNewswire/ -- Mr. NoppadonPakprot, Deputy Governorfor Tourism Products and Business,Tourism Authority of Thailand (TAT) presided over the Amazing Thailand Health and Wellness Tourism Showcase 2017 yesterday, which unveiled the latest "Functional & Regenerative Medicine" innovation in Thailand.

Mr. NoppadonPakprot, Deputy Governorfor Tourism Products and Business at TAT said, "Thailand has long been recognized as a world destination for medical tourism. According to a report by VISA and Oxford Economics, Thailand has once more been confirmed as one of Asia's top medical tourism destinations. Thailand now has 58 JCI-accredited hospitals, more than any other Southeast Asian country."

The Amazing Thailand Health and Wellness Tourism Showcase 2017, under the concept "Thailand: a Paradise for Longevity", showcased Thailand as a destination for longevity products and services.

Thailand has adopted the latest innovative medicine of the century: "Functional & Regenerative Medicine," the most popular health trend in the world. In fact, Thailand is the first and only country in Asia that has specialized Functional & Regenerative Medicine hospitals, namely Better Being Hospital and MALI hospital

Moreover, Thailand has become an anti-aging center in Asia with the largest number of American Academy of Anti-Aging Medicine-certified medical professionals in Asia with 500 doctors.

"Recently, the government implemented new medical tourism policies extending the visitor stay period to 90 days for members of CLMV countries andTaiwan in order to accommodate medical tourists traveling to Thailand. In addition, the long-stay visa has also been extended to 10 years for 14 countries as follow: Japan, Australia, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Sweden, Switzerland, UK, Canada and the U.S. These two recent policies should further enhance the positioning of Thailand to be a world-class medical tourism hub recognized the world over."

Mr. Noppadonnoted: "This is the 4th such event that TAT has organized, and this year we proudly present the top 44 Health and Wellness providers in Thailand. This event will display the potential of Thailand along with its plethora of health and wellness products to international awareness. It will also provide a marketing platform for Thai health and wellness providers to discuss prospective business deals with medical tourism facilitators and travel agencies from across the globe."

The one-day event highlighted why Thailand is a "Paradise for Longevity", along with holding an informative presentation on the concept of "Functional & Regenerative Medicine. In the afternoon, buyers had the chance to discuss business deals with the top 44 health and wellness providers in Thailand, including: General Hospital, Plastic Surgery Hospital, Regenerative Functional Medicine Hospital, Anti-Aging Clinic, Cosmetic & Aesthetic Clinic, Dental Clinic, Cell Therapy Clinic, and Lab Check Up, all of whom were ready to discuss prospective business deals with international buyers.

Mr. NoppadonPakprot concluded as follows: "We hope that this event will further strengthen the awareness of Thailand as the premier destination for health and wellness tourism, and that the trade event would help generate more than 500 million Baht to the Thai economy."

Ms. Jittima Udayachalerm, Director, Royal Orchid Plus Business Unit said, "Royal Orchid Plus is delighted to be part of this global medical tourism event at this time. We've created exciting marketing activities to support this project. "We've organized a special event, inviting Royal Orchid Plus Platinum and Gold members to come and get health check-ups for free, and also given them the chance to meet and buy special packages from the hospitals and clinics at the event. Additionally, we will promote an exclusive health and wellness deal to Royal Orchid Plus members through our online channels, including email, social media, and our website."

SOURCE Amazing Thailand Health and Wellness Tourism Showcase 2017

View original post here:
TAT holds global medical tourism event: "Amazing Thailand Health and Wellness Tourism Showcase 2017," focusing ... - Markets Insider

By The Canton Repository Editorial Board

There's a lot of excitement aboutOhio State University.

That's not unusual at this time of year. After all, the Buckeyes are getting closer to kicking off the 2017 football season.

But, as exciting as their games are each week, what they've got going on pales in comparison to what some researchers are doing at Ohio State's Wexner Medical Center.

In a historic breakthrough, they're helping to save lives, cell by cell. They've successfully turned skin cells into the types of cells the body might need.

What does that mean? The Columbus Dispatch broke it downin a story published last week: "... a technology that has limitless potential, from regenerating a wounded limb to repairing a brain after stroke to healing a damaged heart."

The ramifications are boundless, as is our joy at this breakthrough.

The work started small, building blood vessels to help regenerate limbs in mouse legs within seven to 14 days. Once officials at Walter Reed National Military Medical Center in Bethesda, Md., expressed interest, the work took on a grander scale, the Dispatch reported. The leg-healing process was duplicated in pigs. It's clear the technology can help troops in the field, but researchers reported that it must begin within 72 hours of injury to be successful.

The process seems so simple. Twenty-six researchers in the fields of engineering, science and medicine worked together to develop the technology that involved placing a square chip about the size of a fingernail on the skin, adding a drop containing a genetic code. It then was zapped with an energy source. Researchers told the Dispatchthe genetic material changes depending on the type of regeneration that is needed.

"It's like a syringe that's the chip but then what you load in the syringe is your cargo," Chandan Sen, director of the Center for Regenerative Medicine and Cell-Based Therapies at Wexner Medical Center, told the Dispatch. "Based on what you intend the cells to be, the cargo will change. So, if you want a vasculogenic (blood vessel) cell, the code would be different than if you wanted a neuro cell, and so on and so forth."

The mind reels when you think of the ways in which such technology could be used. Ohio State carefully worked on this project, with funding from private sources because of the high risk of failure, and is preparing to seek approvalfrom the Food and Drug Administration to try it out on humans.

The good news on this project extends to Ohio's economy, because a Columbus company is manufacturing the chips, and it already has drawn interest from a Taiwan-based company. L. James Lee, a professor of chemical and biomolecular engineering at OSU and another of the leading researchers on the project, said the team is looking toprove feasibility within a year.

It's wonderful to see such thoughtful and valuable projects accomplished in Ohio, and for the state to benefit furtherfrom the idea. Ohio is home to a wealth of premier medical institutions, and this is another way the state is shining brightly in a field with tremendous growth potential.

Congratulations to the team at Ohio State. You're champions to us!

Go here to read the rest:
Editorial: Cell regeneration work a boon to Ohio, health care - Canton Repository

The field is called regenerative medicine, technology that shows promise of repairing or replacing human organs with new ones, healing injuries without surgery and, someday, replacing cartilage lost to osteoarthritis.

New Hampshire could become one of the centers of the new industry and become the next Silicon Valley, says Manchester inventor Dean Kamen. The governor and Legislature, however, arent doing what they need to make the potential economic and intellectual boom more likely.

Sever the spinal chord of a zebra fish, an aquarium standby, and it will regrow in a couple of weeks. Remove a limb from a salamander, and it will grow another one indistinguishable from the first. And even some humans, especially when young, can regrow a new fingertip and fingernail on a digit severed above its last joint. Medical science is moving ever closer to performing such wonders.

3-D bioprinters that use biologic materials instead of printer ink are already printing replacement human skin. A University of Connecticut scientist and surgeon believes it will be possible to regenerate human knees sometime in the next decade and regrow human limbs by 2030.

At Ohio State University, a team has succeeded in using genetic material contained in a tiny microchip attached to skin and, with a tiny, Frankenstein-like zap of electricity, reprogram skin cells to produce other types of human cells. Turn a skin cell into say, a vascular system cell, and it will migrate to the site of a wound, spur healing and restore blood flow. Convert skin cells to brain cells and, with a few more steps, it could help stroke victims recover. The technologys potential is enormous.

Kamen created the portable insulin pump, and he and his team at DEKA Research in Manchesters millyard produced the Segway human transporter, a device that provides clean water in places that lack it, an external combustion engine that will soon heat and power part of the states mental hospital, and other inventions. Their track record helped Kamen and DEKA beat out plenty of other applicants to win $80 million in federal funds to found ARMI, the Advanced Regenerative Manufacturing Institute in Manchester. Total funding is now just shy of $300 million.

The governments aim is to spur technologies that could be used to treat injured soldiers but whats learned could aid everyone and make New Hampshire a mecca for scientists, production facilities, pharmaceutical companies and more. DEKA will not create the new technologies but use its inventing and engineering expertise to help companies scale up and speed up regenerative medicine technologies so they can be brought to the market more quickly at an affordable cost.

The states university system has partnered with DEKA to train students who will one day work in the biotech field. The educational infrastructure is in place, but its handicapped by the states sorry funding of higher education. New Hampshire regularly ranks last or next to last in state support and its students carry the most debt of any in the nation.

To make New Hampshire the biotech mecca Kamen envisions will require lawmakers to better fund higher education, support the regenerative manufacturing institute and make housing available. A high-tech company that wants to come to New Hampshire cant do so if its workers cant afford a home.

Regenerative medicine is expected to become a massive economic engine, one that will create jobs and improve lives while lowering health care costs. The Legislature should be doing all it can to make sure that at least some of that engine is designed and made in New Hampshire.

See the article here:
Editorial: The growth of regenerative medicine - Concord Monitor

Scientists are making use of discarded animal organs by turning them into origami but its more than just an art project.

A team of researchers at Northwestern University created the paper cranes to demonstrate the flexibility and malleability of their latest breakthrough: a tissue paper that has the potential to heal wounds, prevent scarring and help hormone production in cancer patients.

This new class of biomaterials has potential for tissue engineering and regenerative medicine as well as drug discovery and therapeutics, Ramille Shah, one of the team members, told Northwestern.edu. Its versatile and surgically friendly.

The tissue paper is a blend of proteins from animal organs that, when wet, can be folded, rolled, cut, flattened, balled, ripped and even crafted into tiny birds. It can also be frozen for later use, making it even more practical.

In one of the first lab tests, the team successfully grew hormone-secreting follicles in a culture using a paper made from a cow ovary. Their findings were recently published in Advanced Functional Materials.

And as with many scientific discoveries, the team at Northwestern stumbled upon the new material as an accident.

The scientists were researching 3D-printed mice ovaries when one of the team members spilled the hydrogel-based gelatin ink used in creating the ovaries. The ink pooled into a dry sheet that ended up being surprisingly strong.

The light bulb went on in my head, Adam Jakus, another one of the team members, told Northwestern.edu. I knew right then I could make large amounts of bioactive materials from other organs.

Since then, the researchers have been collecting scrap pig and cow organs from a local butcher and using them to further test out the regenerative tissue paper.

Breaking down everything from animal uteruses to kidneys to muscles to hearts, the team extracts the structural proteins which give an organ its form then dries them out and combines it was a polymer, or resin, which generates the thin, paper structure.

The final product is basically a papier-mch-like sheet of proteins that can retain the biochemicals needed to regenerate a sick or injured piece of tissue, like a human liver, or skin laceration.

Though a lot more research is needed, the material could one day be used to accelerate healing after surgery and help treat hormone deficiencies in cancer patients. The researchers also found it can support human stem cell growth.

It is really amazing that meat and animal by-products like a kidney, liver, heart and uterus can be transformed into paper-like biomaterials that can potentially regenerate and restore function to tissues and organs, Jakus said. Ill never look at a steak or pork tenderloin the same way again.

Read more:
'Origami organs' could be the future of regenerative medicine - New York Post

First Annual Meeting Will Host Healthcare Administrators and Practitioners to Highlight Stem Cell Research Advances and Applications Through Expert Panel Discussions

Freeport, Grand Bahama (PRWEB) August 09, 2017

Okyanos Center for Regenerative Medicine has announced its First Annual Regenerative Medicine Symposium will take place at the Pelican Bay Hotel in Freeport, Grand Bahama on September 27, 2017. This daytime event is free to attend, however space is limited and pre-registration is required.

With oversight from the Ministry of Health's National Stem Cell Ethics Committee (NSCEC) and regulations laid out in the Stem Cell Research and Therapy Act passed in 2013, The Bahamas remains a leader in the global regenerative medicine community. Okyanos Center for Regenerative Medicine was the first cell therapy facility to meet the required standards and began treating patients in 2014.

Healthcare practitioners and administrators are encouraged to participate in the upcoming symposium which will feature specialist presentations, expert panel discussions and live Q&A sessions. The symposium will conclude in time for guests to attend the Okyanos-sponsored Grand Bahama Medical and Dental Association (GBMDA) welcome cocktail reception which will take place at 6:00pm on September 27th at the Pelican Bay.

"It is great to have this year's Grand Bahama Medical and Dental Association conference coordinated with the regenerative medicine symposium," said Dr. Vincent Burton who serves as Okyanos President and Chief Anesthesiologist as well as Vice President of the GBMDA. "The partnership we have forged should ensure an abundance of learning and networking opportunities for attendees."

Director of Research and Development Marc Penn, MD, PhD, FACC, will moderate the informative sessions and address the symposium to share an overview of Okyanos' planned research foci and strategic direction. "Through this annual meeting and others like it, we hope to encourage ongoing discussions which are critical to the development of the regenerative medicine industry both locally and internationally," said Dr. Penn.

To learn more and to register for Okyanos' First Annual Regenerative Medicine Symposium, please visit the Okyanos website.

ABOUT OKYANOS CENTER FOR REGENERATIVE MEDICINE (OH KEY AH NOS): Combining state-of-the art technologies delivered in a cell therapy center of excellence, Okyanos Center for Regenerative Medicine is a leading adult stem cell therapy provider located in Freeport, Grand Bahama. Okyanos was founded in 2011 and is licensed and accredited by the Bahamas' National Stem Cell Ethics Committee (NSCEC) under the Bahamas Stem Cell Therapy and Research Act to provide cell therapy to patients with chronic medical needs that, per scientific research, clinical trials and application, can be safely and potentially efficaciously treated with patients' own adipose-derived stem and regenerative cells. The literary name Okyanos, the Greek god of the river Okeanos, symbolizes restoration of blood flow. Learn more at http://www.okyanos.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/08/prweb14585069.htm

See the rest here:
Okyanos Center for Regenerative Medicine to Hold Stem Cell Symposium in Freeport - Benzinga

COLUMBUS, Ohio (CBSNewYork) It sounds like something out of a sci-fi novel a microchip that rescues injured or failing organs.

As CBS2s Dr. Max Gomez reported Tuesday, the breakthrough in regenerative medicine is actually being tested right now.

One of the hottest areas of medical research is using cells instead of drugs to treat diseases and injuries. But cellular therapies require finding or making the right type of cells, which can be difficult.

It turns out the body can do it on its own, with a little high-tech help.

The device is only about the size of a cufflink, but what it could represent is enormous. In a laboratory at the Ohio State University Wexner Medical Center, researchers demonstrated how it reprograms cells.

The chip is simply placed on an injured part of the body and a small electrical current is applied.

This process only takes less than a second and is non-invasive and then youre off, said Dr. Chan of Ohio State Wexner Medical Center. The chip does not stay with you, and the reprogramming of the cell starts.

That reprogramming turns skin cells into nearly any type of cell doctors might need to treat a patient a breakthrough technology in regenerative medicine.

For example, in a leg that is badly injured and lacks blood flow, doctors simply touch the chip to the leg and reprogram the skin to become functioning blood vessels.

And it will quickly shoot the DNA right into the cells, said Dr. James Lee of the Ohio State College of Engineering.

In many cases in seven days, you start seeing changes and these changes to our pleasant surprise persists, Dr. Sen said.

Within a week, there are active blood vessels and by the second week, the leg is saved.

It is important to note that the procedure has not yet been tested in humans. But after developing the concept, researchers were determined to test it in real life.

So we tried them on the mouse and put it on the skin, and you know what? It actually works, said Dr. James Lee of the Ohio State College of Engineering. It affects the entire tissue, not just the surface.

An image shows the mouses leg is injured, and vascular scans show there is little blood flow. But after one touch with the chip, in just three weeks, the blood flow was back and the injured leg was saved.

Our technology is not just limited to be used on the skin, Dr. Sen said. It can be used in other tissues within the body or outside the body, so on and so forth. So, skin is only one example.

In fact, in lab tests the chip even worked in the brain helping mice recover from strokes. In humans, it could allow doctors to grow brain cells on a persons skin under the guidance of their own immune system.

They could then harvest the cells and inject them into the brain to treat conditions such as Alzheimers disease and Parkinsons disease without any immune suppression drugs being necessary.

The electrical current actually opens up channels in the skin cells that allow the delivery of factors that are known to change the expression of certain genes in those cells. Better yet, the reprogramming doesnt have to be in a hospital setting because there is nothing invasive about it.

Read the rest here:
Microchip May Fix Damaged Cells And Organs, Scientists Say ... - CBS New York

LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the regenerative medicine market in the US is expected to grow at a CAGR of almost 24% during the forecast period.

This research report titled Regenerative Medicine Market in the US 2017-2021 provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecasts for various market segments and all geographical regions.

The regenerative medicine market in the US is expected to grow at a rapid pace during the forecast period. The major factors that are driving the demand for regenerative products are increasing investments in R&D activities and the rising incidence of chronic diseases. Leading vendors have increased their R&D investments to develop innovative medical therapies, which is driving the overall growth of the market. M&A and strategic alliances among vendors will have a significant impact on the market growth.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

Technavios healthcare and life sciences research analysts categorize the regenerative medicine market in the US into the following segments by end-user. They are:

Looking for more information on this market? Request a free sample report

Technavios sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Hospitals

Hospitals are the key end users in the market, which form a partnership with regenerative medicine manufacturing companies to provide cell therapy and tissue scaffolds to improve patient care and treatment. The increasing number of wound treatment, craniomaxillofacial surgery, knee replacement cases, and soft tissue repair has increased the demand for cell therapy and tissue scaffolds in the market.

According to Srinivas Sashidhar, a lead orthopedics and medical devices research analyst from Technavio, Hospitals provide cell therapy in outpatient settings to reduce the cost burden on the patient. The Centers for Medicare and Medicaid Services provides reimbursement to the hospitals based on the Current Procedural Terminology code and the type of cell or tissue scaffold product. A minimal amount is paid to the physician who performs the procedure. Most of the hospitals have budget constraints and are required to reduce medical expenses. This has made many hospitals to avoid purchasing the high-cost regenerative medicines.

ASCs

There is an increased need for monitoring chronic conditions outside hospitals. The growing focus toward offering more consumer-friendly outpatient services and locations has increased the demand for ASCs. Individuals who have received vital signs monitoring in emergency rooms will step into urgent care centers. ASCs have a limited number of suppliers.

The government in the US focuses on reducing overall hospital costs. Governments pay low reimbursements in these centers compared with hospitals, which helps in making profits. In addition, these centers offer better patient care, and people can go through the same services offered in hospitals at a lower cost, which will lead to an increase in surgical procedures in these centers, adds Srinivas.

Regenerative medicine centers

Regenerative medicine centers are certified clinics that offer healthcare services to people. These centers have specialized departments for regenerative medicine, which offer care and treatment. For instance, the Regenerative Medicine Clinic at the Cedars-Sinai Heart Institute offers treatment and consultation for heart patients. For such patient pool, the clinic investigates the effect and efficiency of stem cell therapy.

Kansas Regenerative Medicine Center in the US provides stand-alone stem cell therapy. It offers autologous adipose-derived stem cell treatments. It contains multidisciplinary physicians to provide treatment to the patients. The skilled professionals conduct mini liposuction procedures to isolate and implant patients source of regenerative cells from the fat tissue.

The top vendors highlighted by Technavios research analysts in this report are:

Browse Related Reports:

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

More:
Regenerative Medicine Market in the US - Forecasts, Segmentation, and Opportunity Assessment by Technavio - Business Wire (press release)

Shares ofChina Regenerative Medicine International Ltd (8158.HK) is moving on volatility today-0.90% or -0.002 from the open.TheHKSE listed companysaw a recent bid of0.22 on1530000 volume.

Dedicated investors often strive hard to set themselves up for success. Finding long-lasting success in the stock market may not be an easy endeavor. The mindset of a short-term trader may differ greatly from that of a long-term investor. Investors often have to be prepared for many different situations. Obtaining the proper knowledge about stocks and the investing world is typically a main goal for active traders and investors. Once the investor is armed with knowledge, they may be able to see things that others cannot. This may involve staying up to date on various fundamentals, technicals, and macro-economic conditions.

Taking a deeper look into the technical levels ofChina Regenerative Medicine International Ltd (8158.HK), we can see thatthe Williams Percent Range or 14 day Williams %R currently sits at -50.00. The Williams %R oscillates in a range from 0 to -100. A reading between 0 and -20 would point to an overbought situation. A reading from -80 to -100 would signal an oversold situation. The Williams %R was developed by Larry Williams. This is a momentum indicator that is the inverse of the Fast Stochastic Oscillator.

China Regenerative Medicine International Ltd (8158.HK) currently has a 14-day Commodity Channel Index (CCI) of -15.72. Active investors may choose to use this technical indicator as a stock evaluation tool. Used as a coincident indicator, the CCI reading above +100 would reflect strong price action which may signal an uptrend. On the flip side, a reading below -100 may signal a downtrend reflecting weak price action. Using the CCI as a leading indicator, technical analysts may use a +100 reading as an overbought signal and a -100 reading as an oversold indicator, suggesting a trend reversal.

The RSI, or Relative Strength Index, is a widely used technical momentum indicator that compares price movement over time. The RSI was created by J. Welles Wilder who was striving to measure whether or not a stock was overbought or oversold. The RSI may be useful for spotting abnormal price activity and volatility. The RSI oscillates on a scale from 0 to 100. The normal reading of a stock will fall in the range of 30 to 70. A reading over 70 would indicate that the stock is overbought, and possibly overvalued. A reading under 30 may indicate that the stock is oversold, and possibly undervalued. After a recent check, China Regenerative Medicine International Ltds 14-day RSI is currently at 44.93, the 7-day stands at 46.99, and the 3-day is sitting at 44.24.

Currently, the 14-day ADX for China Regenerative Medicine International Ltd (8158.HK) is sitting at 22.53. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would support a strong trend. A value of 50-75 would identify a very strong trend, and a value of 75-100 would lead to an extremely strong trend. ADX is used to gauge trend strength but not trend direction. Traders often add the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) to identify the direction of a trend.

Excerpt from:
China Regenerative Medicine International Ltd (8158.HK) Reaches Active Mover List - Morgan Research